(PharmaNewsWire.Com, September 28, 2017 ) According to the recently published report 'Aurora Kinase A-Pipeline Review, H2 2017'; Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) pipeline Target constitutes close to 14 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes.
Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1)-Aurora kinase A also known as serine/threonine-protein kinase 6 is an enzyme that contributes to the regulation of cell cycle progression. It plays a critical role in various mitotic events including the establishment of mitotic spindle, centrosome duplication, centrosome separation as well as maturation, chromosomal alignment, spindle assembly checkpoint, and cytokinesis. It is required for initial activation of CDK1 at centrosomes and normal axon formation. It phosphorylates numerous target proteins, including ARHGEF2, BORA, BRCA1, CDC25B, DLGP5, HDAC6, KIF2A, LATS2, NDEL1, PARD3, PPP1R2, PLK1, RASSF1, TACC3, p53/TP53 and TPX2. It regulates KIF2A tubulin depolymerase activity.
The report 'Aurora Kinase A-Pipeline Review, H2 2017' outlays comprehensive information on the Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I and Preclinical stages are 4, 2 and 6 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Oncology which include indications Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Anaplastic Large Cell Lymphoma (ALCL), Solid Tumor, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Colon Cancer, Metastatic Breast Cancer, Neuroblastoma, Ovarian Cancer, Anaplastic Astrocytoma, B-Cell Chronic Lymphocytic Leukemia, Brain Tumor, Breast Cancer, Burkitt Lymphoma, Central Nervous System (CNS) Tumor, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Cutaneous Angiosarcoma, Diffuse Large B-Cell Lymphoma, Ependymoma, Follicular Lymphoma, Gastric Cancer, Glioblastoma Multiforme (GBM), Gliosarcoma, Hepatocellular Carcinoma, High-Grade Glioma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Kidney Cancer (Renal Cell Cancer), Lymphoma, Malignant Pleural Mesothelioma, Mantle Cell Lymphoma, Marginal Zone B-cell Lymphoma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Nasopharyngeal Cancer, Neuroendocrine Cancer, Non-Small Cell Lung Cancer, Oligodendroglioma, Pilocytic Astrocytoma, Prostate Cancer, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Soft Tissue Sarcoma, Subependymal Giant Cell Astrocytoma, Testicular Cancer and Waldenstrom Macroglobulinemia.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
List of Tables Number of Products under Development by Stage of Development, H2 2017 Number of Products under Development by Therapy Areas, H2 2017 Number of Products under Development by Indications, H2 2017 Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 Number of Products under Development by Indications, H2 2017 (Contd..2), H2 2017 Number of Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Products under Development by Companies, H2 2017 (Contd..2), H2 2017 Products under Development by Companies, H2 2017 (Contd..3), H2 2017 Number of Products under Investigation by Universities/Institutes, H2 2017 Products under Investigation by Universities/Institutes, H2 2017 Number of Products by Stage and Mechanism of Actions, H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Pipeline by AbbVie Inc, H2 2017 Pipeline by Amgen Inc, H2 2017 Pipeline by CASI Pharmaceuticals Inc, H2 2017 Pipeline by Cielo Therapeutics Inc, H2 2017 Pipeline by Merck & Co Inc, H2 2017 Pipeline by Millennium Pharmaceuticals Inc, H2 2017 Pipeline by Sanofi, H2 2017 Pipeline by Sareum Holdings Plc, H2 2017 Pipeline by Sigma-Tau SpA, H2 2017 Pipeline by Taiho Pharmaceutical Co Ltd, H2 2017 Dormant Products, H2 2017 Dormant Products, H2 2017 (Contd..1), H2 2017 Dormant Products, H2 2017 (Contd..2), H2 2017 Dormant Products, H2 2017 (Contd..3), H2 2017 Dormant Products, H2 2017 (Contd..4), H2 2017 Dormant Products, H2 2017 (Contd..5), H2 2017 Discontinued Products, H2 2017 Discontinued Products, H2 2017 (Contd..1), H2 2017
List of Figures Number of Products under Development by Stage of Development, H2 2017 Number of Products under Development by Top 10 Indications, H2 2017 Number of Products by Stage and Mechanism of Actions, H2 2017 Number of Products by Routes of Administration, H2 2017 Number of Products by Stage and Routes of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
